Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group Inc (REPL) is a clinical-stage biotechnology leader advancing oncolytic immunotherapies through its proprietary RPx platform. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access a centralized repository of press releases, financial reports, and scientific updates related to Replimune’s pipeline candidates RP1, RP2, and RP3. Track progress in viral gene therapy for solid tumors, partnership announcements, and strategic initiatives shaping the future of cancer treatment.
Key updates include clinical trial results, FDA designations, collaboration agreements, and financial performance. Our curated news feed ensures you stay informed about breakthroughs in immunogenic cell death research and combination therapy strategies.
Bookmark this page for streamlined access to Replimune’s latest developments. Check regularly for authoritative updates on innovations in oncolytic immunotherapy and their implications for oncology care.
Rhea-AI Summary
Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
-
Rhea-AI Summary
Replimune Group, Inc. grants inducement equity awards to Carolyn Trott, the new Senior Vice President, Quality Assurance, comprising a stock option for 75,000 shares and restricted stock units for 50,000 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
-
Rhea-AI Summary
Replimune Group, Inc. announces leadership changes to support commercialization efforts for RP1 biologics. Sushil Patel to succeed Philip Astley-Sparke as CEO. RP1 BLA submission planned for 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
Rhea-AI Summary
Replimune Group, Inc. announces presentations at AACR Annual Meeting 2024 for RP1 and RP2 oncolytic immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
-
Rhea-AI Summary
Replimune Group, Inc. announces participation in three upcoming investor conferences to present oncolytic immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
-
Rhea-AI Summary
Replimune Group, Inc. (Nasdaq: REPL) announced positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma, demonstrating durability of response. Centrally reviewed 12-month primary analysis data from IGNYTE trial of RP1 in anti-PD1 failed melanoma and biologics license application (BLA) submission expected in 2H 2024. Phase 3 confirmatory trial of RP1 in anti-PD1 failed melanoma skin cancers expected to initiate 2H 2024. Cash runway extended to fund operations into 2H 2026. CEO Philip Astley-Sparke expressed optimism about the potential of RP1 as a safe and effective treatment option for patients with different skin cancers, planning to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024 and explore potential additional submissions based on evolving data from multiple non-melanoma skin cancer studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
Rhea-AI Summary
DISCO Pharmaceuticals, a specialist biotech company, has emerged from stealth with a transformative surfaceome discovery technology to identify new targets and develop first-in-class drugs for cancer treatment. The company has successfully raised seed financing of EUR 20 million and is backed by a world-leading investor syndicate. DISCO has completed the first-ever map of the surfaceome of Small Cell Lung Cancer and is developing proprietary antibody-based treatments for it. The company is also working on Microsatellite-Stable Colorectal Cancer and has a pipeline of further undisclosed programs. The experienced team, led by CEO Roman Thomas, includes leading biopharma executives Dieter Weinand and Carsten Reinhardt. The company's surfaceome mapping platform has the potential to transform oncology treatment options and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
-
Rhea-AI Summary
Replimune Group, Inc. (Nasdaq: REPL) announced that CEO Philip Astley-Sparke will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The company is a clinical stage biotechnology firm focusing on oncolytic immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
-
Rhea-AI Summary
Replimune Group, a clinical stage biotechnology company (NASDAQ: REPL), announced results from the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial. The company also shared a new data snapshot from the IGNYTE cohort of anti-PD1 failed non-melanoma skin cancer (NMSC) patients and data from the ARTACUS trial evaluating RP1 as monotherapy for skin cancer in patients who have had solid organ or hematopoietic cell transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.21%
Tags
Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL) announced updated data from a Phase 1 study of RP2 in metastatic uveal melanoma patients, showing a 29.4% overall response rate and a median duration of response of 11.47 months. The treatment was generally well tolerated with no grade 4 or 5 adverse events. Dr. Joseph Sacco presented the data at the 20th International Congress of the Society for Melanoma Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
Replimune Group
Nasdaq:REPL
REPL Rankings
REPL Stock Data
587.62M
72.42M
4.18%
101.93%
11.87%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
WOBURN